A meta-analysis on CSF neurogranin levels for the diagnosis of Alzheimer's disease and mild cognitive impairment.

Ioannis A MavroudisFoivos PetridisSymela ChatzikonstantinouDimitrios Kazis

Published in: Aging clinical and experimental research (2019)

Neurogranin could be added to the panel of existing biomarkers for a more accurate diagnosis and progress of AD and assessment of underlying pathological changes in the brain.

Keyphrases

mild cognitive impairment
cognitive decline
resting state
high resolution
multiple sclerosis
functional connectivity